Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,085 Mln
Revenue (TTM)
$1,226 Mln
Net Profit (TTM)
$28 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
75
P/B Ratio
2.6
Industry P/E
44.78
EV/EBITDA
19.4
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$--
EPS
$0.5
Face value
--
Shares outstanding
52,449,200
CFO
$1,628.66 Mln
EBITDA
$1,884.66 Mln
Net Profit
$194.51 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NuVasive (NUVA)
| -3.6 | -0.6 | 0.3 | -12.3 | -8.0 | -10.5 | 5.5 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
NuVasive (NUVA)
| -21.4 | -6.8 | -27.2 | 56.1 | -15.2 | -13.2 | 24.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NuVasive (NUVA)
|
39.8 | 2,084.9 | 1,226.2 | 28.5 | 6.1 | 3.2 | 75 | 2.6 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,595.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.3 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,954.3 | 1,541.6 | 233.6 | 21.6 | 21.4 | 22.3 | 4.5 | |
| 178.6 | 9,592.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.8 | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,634.7 | 738.3 | 48.9 | 11.4 | 2.4 | 137 | 3.2 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive... surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc. Read more
CEO & Director
Mr. J. Christopher Barry
CEO & Director
Mr. J. Christopher Barry
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of NuVasive Inc (NUVA) is $39.75 (NASDAQ) as of 08-Sep-2023 09:30 EDT. NuVasive Inc (NUVA) has given a return of -8.04% in the last 3 years.
The P/E ratio of NuVasive Inc (NUVA) is 75.00 times as on 08-Sep-2023, a 67 premium to its peers’ median range of 44.78 times.
The P/B ratio of NuVasive Inc (NUVA) is 2.62 times as on 08-Sep-2023, a 11 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
64.06
|
2.98
|
|
2021
|
-42.37
|
3.41
|
|
2020
|
-78.64
|
3.18
|
|
2019
|
64.78
|
4.62
|
|
2018
|
208.62
|
3.12
|
The 52-week high and low of NuVasive Inc (NUVA) are Rs -- and Rs -- as of 05-Apr-2026.
NuVasive Inc (NUVA) has a market capitalisation of $ 2,085 Mln as on 08-Sep-2023. As per SEBI classification, it is a company.
Before investing in NuVasive Inc (NUVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.